Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Lois Krahn"'
Autor:
Anne Marie Morse, Lois Krahn, Julie Flygare, Clete Kushida, Michael J. Thorpy, Amod Athavale, Jennifer Gudeman
Publikováno v:
Advances in Therapy.
Autor:
Luis Ortiz, Anne Morse, Lois Krahn, Maggie Lavender, Matthew Horsnell, Dianna Cronin, Beth Schneider, Jennifer Gudeman
Publikováno v:
SLEEP. 46:A268-A269
Introduction Individuals with narcolepsy were surveyed to better understand desired treatment outcomes and how those outcomes map to commonly experienced symptoms, treatment awareness, and medication usage. Methods In February 2022, an email invitati
Autor:
Lois Krahn, Melissa Lipford, Gajinder Pal Singh, Shahir Asfahan, J Layne Moore, Maja Tippmann-Peikert, Praveen Kumar-M, Wui Ip, Samir Awasthi, Jennifer Gudeman
Publikováno v:
SLEEP. 46:A256-A257
Introduction Sodium oxybate (SXB) is strongly recommended for treatment of narcolepsy. Patients treated with available immediate-release oxybates are required to awaken for a second dose 2.5–4 hours after the bedtime dose to cover a full night of s
Autor:
Luis Ortiz, Anne Morse, Lois Krahn, Maggie Lavender, Matthew Horsnell, Dianna Cronin, Beth Schneider, Jennifer Gudeman
Publikováno v:
SLEEP. 46:A262-A262
Introduction Research was undertaken to better understand the path to a narcolepsy diagnosis, common symptoms, and the impact of narcolepsy on work, social interactions, and mental health. Methods In February 2022, an email invitation to an online, 2
Autor:
Melissa Lipford, Shahir Asfahan, Gajinder Pal Singh, J Layne Moore, Maja Tippmann-Peikert, Praveen Kumar-M, Wui Ip, Samir Awasthi, Jennifer Gudeman, Lois Krahn
Publikováno v:
SLEEP. 46:A253-A253
Introduction Narcolepsy is a chronic sleep disorder with multiple comorbid conditions. Sodium oxybate (SXB) is strongly recommended for treatment of narcolepsy. This study used aggregate electronic health record (EHR) data to characterize demographic
Autor:
Anne Marie Morse, Lois Krahn, Clete Kushida, Michael Thorpy, Julie Flygare, David Seiden, Amod Athaval, Jennifer Gudeman
Publikováno v:
Sleep. 45:A181-A182
Introduction Immediate-release sodium oxybate (SXB) and mixed-salt oxybates require patients with narcolepsy to take a second nightly dose 2.5–4 h after the first. Extended-release, once-nightly SXB (ON-SXB; FT218) is an investigational treatment f
Autor:
Chad Ruoff, Yasemin Tashman, Bernie Miller, Ryan Houser, Kamal Cheema, Caitlin Haley, Ann Petersen, Matthew Lizak, Umesh Goswami, Trevor Lizak, Lois Krahn, Komandoor Srivathsan
Publikováno v:
Sleep. 45:A342-A343
Introduction Placing a magnet over a Permanent Pacemaker (PPM) or Implanted Cardioverter-Defibrillator (ICD) may cause the device to pace asynchronously or inhibit tachyarrhythmia detection, respectively, potentially preventing delivery of electrical
0407 Early Efficacy With Once-Nightly Sodium Oxybate (ON-SXB; FT218): Post-hoc Analyses From REST-ON
Autor:
Lois Krahn, Asim Roy, John Winkelman, Ann Marie Morse, David Seiden, Jordan Dubow, Jennifer Gudeman
Publikováno v:
Sleep. 45:A182-A182
Introduction Extended-release once-nightly sodium oxybate (ON-SXB; FT218) is in development for adults with narcolepsy. In REST-ON, significant improvements on the Maintenance of Wakefulness test, Clinical Global Impression of Improvement rating, and
Autor:
Anne Marie Morse, Lois Krahn, Clete Kushida, Michael Thorpy, Julie Flygare, David Seiden, Amod Athavale, Jennifer Gudeman
Publikováno v:
Sleep. 45:A181-A181
Introduction Currently available immediate-release sodium oxybate (SXB) and mixed-salt oxybates are dosed twice nightly (second 2.5–4 hours after first). Extended-release, once-nightly SXB (ON-SXB; FT218) is in development. To characterize drivers
Autor:
Chad Ruoff, Erick St Louis, Joseph Cheung, Diego Carvalho, Bethany Larson, Michael Silber, Suresh Kotagal, Lois Krahn, Joshua Bornhorst
Publikováno v:
Sleep. 45:A172-A172
Introduction Orexin deficiency in cerebrospinal fluid (CSF) was first reported in human narcolepsy in 2001, included in diagnostic criteria for narcolepsy in 2014, and made clinically available at the Mayo Clinic in 2019. The purpose of this publicat